Cayman CUDC-305

CUDC-305 is an orally bioavailable inhibitor of heat shock protein 90 (Hsp90; Item Nos. | ). It binds to Hsp90α and Hsp90β (IC₅₀s = 100 and 103 nM for purified protein, respectively) as well as Hsp90 isolated from non-small cell lung cancer (NSCLC) cells resistant to erlotinib (Item No. ; IC₅₀ = 70 nM).^, CUDC-305 induces degradation of Hsp90 client proteins in BT-474 breast cancer cells and inhibits proliferation of 40 human cancer cell lines (IC₅₀s = 0.04-0.9 µM). It also reduces the levels of several oncoproteins including Akt and phosphorylated Akt, and ERK1/2 and phosphorylated ERK1/2 in a variety of cancer cell lines. CUDC-305 (40-160 mg/kg) dose-dependently reduces tumor growth in a U87MG glioblastoma mouse xenograft model and, when administered at a dose of 160 mg/kg, prolongs survival in a U87MG mouse orthotopic model.

WARNING This product is not for human or veterinary use.